This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), aims to develop a Totally-Implanted Left Ventricular Assist Device (TI-LVAD). The TI-LVAD is designed to reduce complications and improve quality of life for heart failure patients, encouraging increased adoption of LVAD treatments. Key features include an ultra-low-power blood pump, implantable battery, and wireless charging capability to eliminate the need for a percutaneous driveline and external power supply. This $1,024,635 award, effective March 1, 2025 through February 29, 2028, will support finalizing the TI-LVAD design, conducting pre-clinical testing, and developing the implanted controller, external programmer, and patient monitoring system. The project is being carried out by Corvion, Inc., a for-profit medical device manufacturer.
Generated 3/18/25, 5:18 AM